FCGRT and myasthenia gravis: Efgartigimod (Efgartigimod alpha fcab, VyvgartTM) is a pioneering neonatal Fc receptor (FcRn) antagonist for the treatment of severe autoimmune diseases mediated by pathogenic immunoglobulin G (IgG) autoantibodies, including myasthenia gravis (MG).